The Effects of Methylphenidate on Knockin Mice with a Methylphenidate-Resistant Dopamine Transporter

Methylphenidate (Ritalin) is one of the most commonly abused prescription drugs. It is a psychostimulant that inhibits the dopamine and norepinephrine transporters with high affinity. In mice, methylphenidate stimulates locomotor activity, is self-administered, and produces conditioned place preference, typical properties of an addictive drug. We have generated a knockin mouse line bearing a mutant dopamine transporter that is approximately 80-fold less sensitive to cocaine inhibition than wild type. It is interesting to note that this mutant is also almost 50-fold less sensitive to methylphenidate inhibition, suggesting similarities in the binding site for cocaine and methylphenidate. Because methylphenidate is not effective at inhibiting the mutant dopamine transporter, we hypothesized that it would not stimulate locomotor activity or produce reward in the knockin mice. In these knockin mice, doses up to 40 mg/kg methylphenidate either inhibit or fail to stimulate locomotor activity and do not produce conditioned place preference. Doses up to 40 mg/kg methylphenidate also fail to produce stereotypy in the knockin mice. Nisoxetine and desipramine, selective norepinephrine transporter inhibitors, also reduce locomotor activity in wild-type and knockin mice. These results indicate that enhanced dopaminergic neurotransmission is required for methylphenidate's stimulating and rewarding effects. In addition, we observed that drugs enhancing noradrenergic neurotransmission inhibit locomotor activity in mice, which is consistent with the notion that methylphenidate's ability to inhibit the norepinephrine transporter may contribute to its efficacy in treating attention deficit hyperactivity disorder.

[1]  David Gottlieb,et al.  Mechanism of Action , 2012, Antibiotics.

[2]  H. Gu,et al.  Dopamine transporter inhibition is required for cocaine-induced stereotypy , 2008, Neuroreport.

[3]  M. West,et al.  Dose- and Rate-Dependent Effects of Cocaine on Striatal Firing Related to Licking , 2008, Journal of Pharmacology and Experimental Therapeutics.

[4]  Jeffrey C. Glennon,et al.  Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder , 2007, Neuroscience & Biobehavioral Reviews.

[5]  B. Cagniard,et al.  Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression , 2007, BMC Neuroscience.

[6]  S. Puglisi‐Allegra,et al.  Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli , 2007, Proceedings of the National Academy of Sciences.

[7]  A. Kelley,et al.  Methylphenidate Preferentially Increases Catecholamine Neurotransmission within the Prefrontal Cortex at Low Doses that Enhance Cognitive Function , 2006, Biological Psychiatry.

[8]  S. McCabe,et al.  Illicit Use of Specific Prescription Stimulants Among College Students: Prevalence, Motives, and Routes of Administration , 2006, Pharmacotherapy.

[9]  L. Kroutil,et al.  Nonmedical use of prescription stimulants in the United States. , 2006, Drug and alcohol dependence.

[10]  E. Hess,et al.  The α2C-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder , 2006, Neurobiology of Disease.

[11]  M. Feliú-Mójer,et al.  Alpha‐Noradrenergic Receptors Modulate the Development and Expression of Cocaine Sensitization , 2006, Annals of the New York Academy of Sciences.

[12]  Robert L Stephens,et al.  Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. Gu,et al.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs , 2006, BMC pharmacology.

[14]  G. Torres,et al.  The dopamine transporter proteome , 2006, Journal of neurochemistry.

[15]  H. Gu,et al.  A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate , 2005, Journal of neurochemistry.

[16]  X. Zhang,et al.  Prazosin, an α-1 Adrenergic Antagonist, Reduces Cocaine-Induced Reinstatement of Drug-Seeking , 2005, Biological Psychiatry.

[17]  J. Glowinski,et al.  5‐HT2A and α1b‐adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants , 2004, The European journal of neuroscience.

[18]  G. Koob,et al.  Treating cocaine addiction with viruses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Sesack,et al.  Ultrastructural interactions between terminals expressing the norepinephrine transporter and dopamine neurons in the rat and monkey ventral tegmental area , 2004, Synapse.

[20]  R. Spealman,et al.  Pharmacological Blockade of α2-Adrenoceptors Induces Reinstatement of Cocaine-Seeking Behavior in Squirrel Monkeys , 2004, Neuropsychopharmacology.

[21]  P. Greengard,et al.  Topographical Assessment of Ethological and Dopamine Receptor Agonist-Induced Behavioral Phenotype in Mutants with Congenic DARPP-32 ‘Knockout’ , 2003, Neuropsychopharmacology.

[22]  Stefano Puglisi-Allegra,et al.  Norepinephrine in the Prefrontal Cortex Is Critical for Amphetamine-Induced Reward and Mesoaccumbens Dopamine Release , 2003, The Journal of Neuroscience.

[23]  N. Volkow,et al.  Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies , 2002, European Neuropsychopharmacology.

[24]  J. Glowinski,et al.  d-Amphetamine Fails to Increase Extracellular Dopamine Levels in Mice Lacking α1b-Adrenergic Receptors: Relationship between Functional and Nonfunctional Dopamine Release , 2002, The Journal of Neuroscience.

[25]  F. Leri,et al.  Blockade of Stress-Induced But Not Cocaine-Induced Reinstatement by Infusion of Noradrenergic Antagonists into the Bed Nucleus of the Stria Terminalis or the Central Nucleus of the Amygdala , 2002, The Journal of Neuroscience.

[26]  J. Kamei,et al.  Prazosin inhibits spontaneous locomotor activity in diabetic mice , 2002, Pharmacology Biochemistry and Behavior.

[27]  J. Glowinski,et al.  α1b-Adrenergic Receptors Control Locomotor and Rewarding Effects of Psychostimulants and Opiates , 2002, The Journal of Neuroscience.

[28]  J S Fowler,et al.  Mechanism of action of methylphenidate: Insights from PET imaging studies , 2002, Journal of attention disorders.

[29]  J. Glowinski,et al.  Critical role of α1‐adrenergic receptors in acute and sensitized locomotor effects of D‐amphetamine, cocaine, and GBR 12783: Influence of preexposure conditions and pharmacological characteristics , 2002, Synapse.

[30]  S. Kollins,et al.  Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review , 2001, Pharmacology Biochemistry and Behavior.

[31]  Fei Xu,et al.  Mice lacking the norepinephrine transporter are supersensitive to psychostimulants , 2000, Nature Neuroscience.

[32]  Joseph Biederman,et al.  Attention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder , 1999, Biological Psychiatry.

[33]  R. Gainetdinov,et al.  Cocaine self-administration in dopamine-transporter knockout mice , 1998, Nature Neuroscience.

[34]  D. Murphy,et al.  Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Gainetdinov,et al.  Cocaine self-administration in dopamine-transporter knockout mice , 1998, Nature Neuroscience.

[36]  D. Segal,et al.  Effects of Methylphenidate on Extracellular Dopamine, Serotonin, and Norepinephrine: Comparison with Amphetamine , 1997, Journal of neurochemistry.

[37]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[38]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Wise,et al.  A psychomotor stimulant theory of addiction. , 1987, Psychological review.

[40]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[41]  Barbara E. Jones,et al.  Ascending projections of the locus coeruleus in the rat. I. axonal transport in central noradrenaline neurons , 1977, Brain Research.

[42]  Barbara E. Jones,et al.  Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study , 1977, Brain Research.

[43]  W. M. Davis,et al.  Noradrenergic role in the self-administration of morphine or amphetamine , 1975, Pharmacology Biochemistry and Behavior.

[44]  L. Goodman,et al.  THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .

[45]  E. Hess,et al.  The alpha(2C)-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. , 2006, Neurobiology of disease.

[46]  X. Zhang,et al.  Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. , 2005, Biological psychiatry.

[47]  M. Leider Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .